Hostname: page-component-586b7cd67f-r5fsc Total loading time: 0 Render date: 2024-11-28T10:49:50.905Z Has data issue: false hasContentIssue false
  • English
  • Français

Methods of estimating vancomycin use in an inpatient setting: days of therapy versus therapeutic drug monitoring–based exposure days

Published online by Cambridge University Press:  07 February 2019

Shutaro Murakami Open the ORCID record for Shutaro Murakami [Opens in a new window] ,
Junko Hiroi ,
Yasuharu Tokuda ,
Ed Casabar  and
Hitoshi Honda
Shutaro Murakami*
Affiliation:
Department of Pharmacy, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan Department of Infection Control, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan
Junko Hiroi
Affiliation:
Department of Pharmacy, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan
Yasuharu Tokuda
Affiliation:
Muribushi Project for Teaching Hospitals, Okinawa, Japan
Ed Casabar
Affiliation:
Department of Pharmacy, Barnes-Jewish Hospital, Washington University Medical Center St Louis, Missouri
Hitoshi Honda
Affiliation:
Department of Infection Control, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan
*
Author for correspondence: Shutaro Murakami, Email: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Underestimating antimicrobial use based on days of therapy (DOT) is recognized for certain antimicrobial agents. We investigated the difference between DOT and therapeutic drug monitoring (TDM)–based exposure days in estimating vancomycin use and demonstrated that DOT may underestimate vancomycin exposure by ∼10%.

Type
Concise Communication
Information
Infection Control & Hospital Epidemiology , Volume 40 , Issue 3 , March 2019 , pp. 375 - 379
Copyright
© 2019 by The Society for Healthcare Epidemiology of America. All rights reserved. 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Polk, RE, Fox, C, Mahoney, A, Letcavage, J, MacDougall, C. Measurement of adult antibacterial drug use in 130 US hospitals: comparison of defined daily dose and days of therapy. Clin Infect Dis 2007;44:664–670.CrossRefGoogle ScholarPubMed
National Healthcare Safety Network (NHSN) antimicrobial use and resistance (AUR) module. Centers for Disease Control and Prevention website. https://www.cdc.gov/nhsn/pdfs/pscmanual/11pscaurcurrent.pdf. Published 2018. Accessed August 20, 2018.Google Scholar
Barlam, TF, Cosgrove, SE, Abbo, LM, et al. Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis 2016;62:e51–e77.CrossRefGoogle Scholar
Kubin, CJ, Alba, LR, Furuya, EY. Lack of significant variability among different methods for calculating antimicrobial days of therapy. Infect Control Hosp Epidemiol 2012;33:421–423.CrossRefGoogle ScholarPubMed
Rybak, M, Lomaestro, B, Rotschafer, JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009;66:82–98.10.2146/ajhp080434CrossRefGoogle Scholar